Galecto

Galecto buys leukemia drug, drops bone cancer asset in pivot

A year after the failure of a fibrosis drug sent Galecto on a search for salvation, the biotech has decided to go all-in on oncology and liver disease

James Waldron Oct 7, 2024 10:07am

An artists depiction of different types of blood cells from bone marrow

Galecto posts myelofibrosis data as search for savior continues

Dec 22, 2023 6:50am

Galecto lays off 70% in wake of fibrosis drug's phase 2 fail

Sep 27, 2023 7:50am

plan B fail reroute road path trail miss

Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver

Aug 15, 2023 7:30am

Galecto travels deeper into liver disease with GULLIVER-2 data

Nov 8, 2022 10:35am

Galecto links blood cancer prospect to reduced fibrosis

Sep 29, 2022 9:20am